MedPath

Diagnostic Biomarkers Exploration of Breast Cancer From Serum and Urine

Recruiting
Conditions
Breast Neoplasm Female
Registration Number
NCT06102018
Lead Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Brief Summary

The goal of this observational study is to find the diagnostic biomarkers in serum and urine from early breast cancer patients. The main questions it aims to answer are:

* compare the different biomarkers in serum and urine from breast cancer patients, benign lesions and healthy population.

* construct the best diagnostic model by machine learning to distinguish breast cancer and non-breast cancer patients.

Participants, including breast and non-breast cancer patients will be asked to provides blood and urine during their diagnosis and treatment process without changing the original treatment. When necessary, specimens will be collected during the surgery,without affecting pathological diagnosis.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
150
Inclusion Criteria
  1. Signing the consent of informedness;
  2. Patients with breast mass who need surgery after examination;
  3. Cardiac ultrasound indicates that the blood score of the heart is within the normal range;
  4. ECOG≤0-2 points;
  5. Oversure function is acceptable.
Exclusion Criteria
  1. Merge other malignant tumors such as gynecologic oncology;
  2. After evaluation, the internal organs are not suitable.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The different biomarkers in malignant and benign breast diseasesIt is expected to be one to two years.

By analyzing the differences (eg:PCA, FC and et al.)in the composition of proteins in blood and urine, biomarkers with significant differences between the two groups will be obtained.

Diagnostic models used different biomarkers by machine learningWithin half a year after the completion of the test.

Using biomarkers that detect discrepancies, combined with machine learning to build early breast cancer diagnostic models.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

🇨🇳

Guangzhou, Guangdong, China

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
🇨🇳Guangzhou, Guangdong, China
Jieqiong Liu
Contact
020-34078091
liujieqiong01@163.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.